Medical/Pharmaceuticals Global News & Press Release Distribution

Medical/Pharmaceuticals

All
APAC

CUREXO's spinal surgery robot, 'CUVIS-spine' acquired FDA (US) licensing.

* 'CUVIS-spine' is available in all countries by acquiring the license from the FDA (US), Korea andEurope. * 'CUVIS-spine' reduces surgery duration with Minimally Invasive Surgery (MIS). SEOUL, South Korea, May 21, 2021 /PRNewswire/ -- On the 20th, the Medical robot specialist company CUREX...

2021-05-22 03:52 2748

CUREXO's spinal surgery robot, 'CUVIS-spine' acquired FDA (US) licensing.

Kintor Announced (1) FDA Has Greenlighted Proxalutamide's Phase III Study for Hospitalized Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide's Phase III Study for Mild to Moderate COVID-19

SUZHOU, China, May 19, 2021 /PRNewswire/ -- On May 18, Kintor Pharmaceutical Limited (HKEX.9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the U.S. Food and Drug Administration (FDA) has greenlighted proxalutamide's ph...

2021-05-20 09:47 8598

Duality Biologics Completed $90 Million Series B Financing

PRINCETON, N.J. and SHANGHAI and SUZHOU, China, May 19, 2021 /PRNewswire/ -- Duality Biologics (DualityBio or Company), an innovative biotech company, announced the completion of$90 million series B financing today. This round of financing was led by Lilly Asia Ventures (LAV) and jointly invested...

2021-05-20 08:00 1443

I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021

* Uliledlimab is a highly differentiated CD73 antibody with a unique epitope that confers pharmacological advantages * Data from U.S. phase 1 dose escalation trial demonstrates favorable safety and tolerability with no dose-limiting toxicities; preliminary clinical activity of uliledlimab has...

2021-05-20 06:00 8170

Gracell Biotechnologies to Present Updated Results of GC012F FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

SUZHOU, China and PALO ALTO, Calif., May 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, is presenting updated ...

2021-05-20 05:15 8358

United Imaging at CMEF Announces uAIFI Technology Platform and uExcel Technology Platform that Advance MR and MI

SHANGHAI, May 19, 2021 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, announced its uAIFI Technology Platform for MR and uExcel Technology Platform for PET/CT at the China International Medical Equipment Fair (CMEF). Al Zhang, Chairman and...

2021-05-19 23:32 1666

ThinkCyte Secures $26 million in Series B Financing

TOKYO, May 19, 2021 /PRNewswire/ -- ThinkCyte, Inc., a company focusing on the development of novel cell therapy, drug discovery and diagnostic platforms, announced today the completion of a $26 million (JPY 2.85 billion) Series B financing, led by SPARX Group with participation from Sysmex Corpo...

2021-05-19 22:00 1928

Island Pharmaceuticals granted key patent for ISLA-101 in the United States

* Island's lead asset, ISLA-101 granted key patent from United Stated Patent & Trademark Office * Patent underpins Island's drug repurposing strategy to rapidly and efficiently develop antiviral therapies with a key focus being mosquito borne viral diseases, such as dengue fever. * Around 3...

2021-05-19 19:30 1395

111, Inc. Announces First Quarter 2021 Unaudited Financial Results

SHANGHAI, May 19, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the first quarte...

2021-05-19 14:17 4810

GeneQuantum Raises Hundreds of Millions RMB in Series C Funding

SUZHOU, China, May 18, 2021 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co., Ltd. (hereinafter "GeneQuantum") announced the completion of Series C fund raising of several hundreds of millions RMB. This series of fund raising is led by China Life Private Equity Investment, jointly by PICC Capi...

2021-05-19 10:30 1509

Cynosure Announces Grand Opening of State-of-the-Art Experience Centre in London

Industry-leading Centre will provide new collaborative and experiential environment for research, training, and treatments LONDON, May 17, 2021 /PRNewswire/ -- Cynosure announced today the grand opening of its new Cynosure Experience Centre inLondon. Complete with new research and training facil...

2021-05-17 16:00 1679

Cynosure Announces Grand Opening of State-of-the-Art Experience Centre in London

China Pharma Holdings, Inc. Reports 33% YoY Increase in First Quarter 2021 Revenue

HAIKOU, China, May 14, 2021 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced financial results for the quarter ended March 31, 2021. Revenue increased by 33.7% to $2.4 million for the thr...

2021-05-15 04:30 9414

Arctic Vision announces exclusive licensing agreement with ActualEyes

To develop and commercialize cell therapy to potentially replace corneal endothelial keratoplasty inGreater China and South Korea * Arctic Vision to partner with ActualEyes to introduce novel approach of using cultured corneal endothelial cells to treat corneal endothelial dysfunction and pote...

2021-05-14 20:00 2778

Arctic Vision announces exclusive licensing agreement with ActualEyes

Luye Life Sciences Unveils Cutting-edge Advances in Gene and Cell Therapy at ASGCT 2021

BOSTON, May 13, 2021 /PRNewswire/ -- The Boston R&D Center and GeneLeap Biotech, two subsidiaries of Luye Life Sciences Group, took part in the 24th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, presenting the progress of four of the company's latest preclinical developments in ...

2021-05-14 11:58 1818

Final Results of Bioavailability Study of Phebra's Oral Arsenic Capsule for Acute Promyelocytic Leukaemia (APL) Confirm Bioequivalence of Oral and IV Formulations

SYDNEY, May 13, 2021 /PRNewswire/ -- Australian pharmaceutical group Phebra (' Company') congratulates the Australasian Leukaemia and Lymphoma Group (ALLG) on the release of their abstract EP433 at the virtual European Hematology Association (EHA) 2021 Conference. The abstract builds on the initi...

2021-05-14 10:33 987

I-Mab Added to MSCI China Index

SHANGHAI and GAITHERSBURG, Md., May 13, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab has been selected for inclusion in the MSCI Ch...

2021-05-13 20:00 4959

An oral antiviral drug from Korea may be a problem solver for COVID-19

SEOUL, South Korea, May 13, 2021 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ 048410) announced that Dr.Jin-Ho Choi, a Chief Scientist of its major shareholding bio tech company CNPharm and Chair Professor at Dankook University, presented the study titled 'COVID-19 Game Changer Drug – a novel orga...

2021-05-13 16:37 1530

An oral antiviral drug from Korea may be a problem solver for COVID-19

Pregene and Dr. Reddy's Announce License Agreement for Anti-BCMA CAR-T PRG1801 in India

BEIJING, May 13, 2021 /PRNewswire/ -- Beijing Time May 10, 2021 — Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) and Shenzhen Pregene Biopharma Co., Ltd. today announced an agreement whereby Dr Reddy's will acquire an exclusive license in the Republic ofInd...

2021-05-13 15:21 1423

Sysmex and ThinkCyte Agree on Joint Development and Capital Alliance

TOKYO, May 12, 2021 /PRNewswire/ -- Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO:Hisashi Ietsugu) and ThinkCyte, Inc. (HQ: Bunkyo-ku, Tokyo, Japan; CEO: Waichiro Katsuda) announced today the signing of joint development and investment agreements duringMay 2021 for the commercializatio...

2021-05-12 22:00 1556

Shaemus Gleason Appointed Executive Vice President US Operations at Clarity Pharmaceuticals

SYDNEY, May 11, 2021 /PRNewswire/ -- Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment ofShaemus Gleason as Executive Vice President U.S. Operations as the company expands its presence, clinica...

2021-05-11 21:04 1605

1 ... 143 144 145146147 148 149 ... 195